AbbVie Enters Partnership to Develop COVID-19 Antibody Therapies

AbbVie has entered a partnership with Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) to develop a monoclonal antibody therapy for COVID-19.

The partnership will advance the fully human, neutralizing antibody 47D11 discovered by UU, EMC and HBM. The drugmaker will support its partners through preclinical activities while preparing for later-stage preclinical and clinical development work.

The company will have the option to exclusively license the antibody for therapeutic clinical development and commercialization worldwide.